In this issue:
RFA after TACE + sorafenib for intermediate-stage recurrent HCC
Atezolizumab-bevacizumab for HCC with viral or nonviral infection
Autoimmune diseases as comorbidities for hepatobiliary cancers
Resection of NAFLD/NASH-related HCC vs. other aetiologies
Nivolumab-cabozantinib ± ipilimumab for advanced HCC
Impact of significant portal hypertension on early-stage HCC posthepatectomy
Disparities in HCC survival by US Medicaid status
First-line lenvatinib vs. atezolizumab-bevacizumab for unresectable HCC
Please login below to download this issue (PDF)